Cocrystal Pharma, Inc. — Director's Dealing 2025

Dec 29, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cocrystal Pharma, Inc. (COCP)
CIK: 0001412486
Period of Report: 2025-12-24

Reporting Person: FROST PHILLIP MD ET AL (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-24	Common Stock	P	25000	$0.9703	Acquired	1728551	Indirect
2025-12-26	Common Stock	P	40000	$0.9736	Acquired	1768551	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	27100	Direct

Footnotes

F1: The price reported in Column 4 for December 24, 2025 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9641 to $0.9803, inclusive. The price reported in Column 4 for December 26, 2025 is a weighted average price. These securities were sold in multiple transactions ranging from $0.9596 to $0.9837, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence.

F2: These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: Includes shares of common stock issuable upon vesting of restricted stock units.